Palbociclib inhibits the binding of CDK4/6 to D type cyclins and has been developed as a promising therapeutic for cancers with altered function of the Cyclin D‐CDK4/6‐p16INK4a pathway (Fry et al., 2004; Otto & Sicinski, 2017). Here, CDK4 is linked to cancer.